Clinical case: the experience of using acetylsalicylic acid, fosinopril and diltiazem in the therapy of a patient with cardiovascular pathology
| Autor: | A. M Nikishenkov, G.G. Shekhyan, A. M Shchikota, T. G Kabanova, V. S Zadionchenko, A. A Yalymov, S. A Terpigorev |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
arterial hypertension lcsh:Diseases of the circulatory (Cardiovascular) system medicine.drug_class calcium channel blocker fosinopril heart failure Calcium channel blocker lcsh:Diseases of the endocrine glands. Clinical endocrinology Nephropathy Fosinopril Internal medicine medicine Diltiazem Myocardial infarction cardiovascular diseases Antihypertensive drug lcsh:RC648-665 biology business.industry diltiazem Angiotensin-converting enzyme acetylsalicylic acid medicine.disease myocardial infarction angiotensin-converting enzyme inhibitor lcsh:RC666-701 Heart failure Cardiology biology.protein nephropathy antiplatelet agents business medicine.drug |
| Zdroj: | КардиоСоматика, Vol 9, Iss 1, Pp 54-60 (2018) |
| ISSN: | 2658-5707 2221-7185 |
| Popis: | The article briefly describes the inhibitor of angiotensin converting enzyme (ACEI) - fosinopril, calcium channel blocker - diltiazem and antiplatelet agent- acetylsalicylic acid (ASA). The mechanism of their action and possible side effects are given. The authors of the article described in detail the antihypertensive drug from the group ACEI - fosinopril, antiplatelet agent - ASA and non-hydropyridine calcium channel blocker - diltiazem. The results of multicenter randomized trials of ASA, fosinopril in patients with arterial hypertension, ischemic heart disease, nephropathy and heart failure are presented. The article presents a clinical example that demonstrates the selection of the optimal drugs for the treatment of the combined pathology of the heart and kidneys, and also provides an evidence base for the efficacy and safety of fosinopril and ASA preparations. Presented drugs (ASA, fosinopril, diltiazem) are highly effective in all categories of patients with CVD and can be recommended for wider clinical use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|